Agent | Alternative name(s) listed on supplement label | Proposed mechanism of activity | Potential adverse effects |
PDE-5 inhibitors (eg, sildenafil, tadalafil, others) | * | PDE-5 inhibitor | Flushing, dyspepsia, headache, visual changes, epistaxis; hypotension with concomitant nitroglycerin, alpha blockers, others[1] |
PDE-5 inhibitor analogs (more than 80 have been identified) | * | Presumed PDE-5 inhibitor activity | May have unexpected adverse effects due to variable PDE receptor activity or off-target activity[1,2] |
Sulfonylureas | * | Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; increases insulin sensitivity | Hypoglycemia, tremor, dizziness |
Yohimbine | Yohimbe, Corynanthe johimbe, coryanthe yohimbe, 11-hydroxy yohimbine | Blocks presynaptic alpha-2-adrenergic receptors, resulting in increased cholinergic and decreased adrenergic tone | Gastrointestinal distress, tachycardia, anxiety/agitation, hypertension[3,4] |
PDE: phosphodiesterase inhibitor.
* Typically not declared/listed on supplement label.Do you want to add Medilib to your home screen?